{
  "id": 19102343,
  "title": "Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%",
  "url": "https://urgent.news/2026/11/09/divis-laboratories-shares-gain-another-5-after-q2-results-heres-why",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T05:09:29.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/stocks/news/divis-laboratories-shares-gain-another-5-after-q2-results-heres-why-jefferies-raised-target-price-by-23/articleshow/135671615.cms"
  },
  "original_language": "en",
  "account": "Divi’s Laboratories experienced a 5% increase in its shares, reaching Rs 11,656, after delivering strong second-quarter results. The pharmaceutical company reported a 64% year-on-year increase in consolidated net profit to Rs 1,127 crore and a 35% increase in revenue from operations to Rs 3,676 crore. Jefferies raised its target price on Divi’s Labs to Rs 12,550 per share from Rs 10,200, citing the company's strong performance in various divisions, including a 50% growth in CDMO business and 18% growth in generics revenue. The brokerage views Divi’s as the best-in-class CRDMO franchise in its coverage universe, with high long-term growth potential and a pipeline of potential blockbuster products.",
  "summary": "Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}